Sirolimus for progression of autosomal dominant polycystic kidney disease with severe renal insufficiency

Phase 2, open-label trial of sirolimus in autosomal dominant polycystic kidney disease (ADPKD) and congenital cystic kidney disease (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Change from baseline in renal function after one year. Started Jul 2008; status: terminated.